Original ArticleA Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500)
Under an Elsevier user license
open archive
Key Words
Small-cell lung cancer
Temsirolimus
CCI-779
Phase II study
Cited by (0)
This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA11083, CA16116, CA21076, CA27525, CA49957 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Copyright © 2007 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.